ストックスクリーナーアプリを入手
21.95
1.79%
-0.40
アフターアワーズ：
21.95
前日終値:
$22.35
開ける：
$22.44
24時間の取引高:
222.82K
Relative Volume:
0.46
時価総額：
$1.08B
収益：
-
当期純損益:
$-85.21M
株価収益率:
-11.61
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-5.96%
1か月 パフォーマンス:
+3.73%
6か月 パフォーマンス:
+0.41%
1年 パフォーマンス:
-8.58%
1日の値動き範囲:
$21.80
$22.83
1週間の範囲:
$21.38
$24.38
52週間の値動き範囲:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.95 | 1.27B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
Polis encourages life-sciences companies to move to Colorado - BizWest
Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional
Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional
Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia
Enliven Therapeutics CSO sells $278k in shares By Investing.com - Investing.com India
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
What drives Enliven Therapeutics Inc. stock priceOutstanding capital growth - Autocar Professional
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Will Enliven Therapeutics Inc. stock split in the near futureTop Performing Low Risk Stocks - Newser
Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks
What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $41.20 - Defense World
Enliven Therapeutics Breaks Above 200-Day Moving AverageBullish for ELVN - Nasdaq
Enliven Therapeutics COO Patel sells shares worth $131950 By Investing.com - Investing.com Canada
Enliven Therapeutics COO Patel sells shares worth $131950 - Investing.com
HC Wainwright Brokers Increase Earnings Estimates for ELVN - Defense World
(ELVN) Long Term Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):